Baird served as co-manager on the offering
AboutKaryopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ-GS:KPTI) recently announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’ option to purchase additional shares. 10,525,424 shares of the Company’s common stock at a price to the public of $14.75 per share were issued and sold in the offering, which includes 1,372,881 shares issued upon the exercise of the underwriters’ option to purchase additional shares. The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $155.25 million.
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has several investigational programs in clinical or preclinical development. Karyopharm is located in Newton, Massachusetts.
CONTACT US TO LEARN MORE
- May 2018
- Karyopharm Therapeutics Inc.
- Target Location
- North America